Biotech Stock Roundup: MRNA Surges, Pipeline Updates From INCY, HRTX & NGM Bio
Zacks Investment Research | Feb 26, 2020 04:42AM ET
As the earnings season comes to an end, the focus is back on pipeline updates from biotech players. While the bigwigs did not come out with much updates, pipeline and regulatory updates took centerstage.
Recap of the Week’s Most Important Stories:
Moderna Surges on Shipping Vaccine Against Coronavirus: Shares of clinical stage biotechnology Moderna, Inc., (NASDAQ:MRNA) surged after it announced the release of the first batch of mRNA-1273, a vaccine against the novel coronavirus. Moderna shipped vials of mRNA-1273 to the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to be used in the planned phase I study in the United States.
mRNA-1273 is an mRNA vaccine against the novel coronavirus, encoding for a prefusion stabilized form of the Spike (S) protein. The candidate was selected by Moderna in collaboration with investigators at the NIAID Vaccine Research Center (VRC).
Incyte Announces Positive Data on Dermatitis Drug: Incyte (NASDAQ:INCY) announced that the second randomized, vehicle-controlled, pivotal phase III study from the TRuE-AD clinical trial program has met its primary endpoint. The TRuE-AD1 and TRuE-AD2 trials both evaluated the safety and efficacy of ruxolitinib cream in adolescent and adult patients (age ≥ 12 years) with mild-to-moderate atopic dermatitis (AD).
Both primary and secondary endpoints were met in TRuE-AD1 and TRuE-AD2 studies. The long-term safety portion of both studies will continue as planned.
Heron Therapeutics Down on Pipeline Setback: Shares of Heron Therapeutics (NASDAQ:HRTX) depreciated after the company announced that the FDA has extended the review period for the New Drug Application (NDA) for pipeline candidate HTX-011 by up to three months. The new PDUFA goal date is Jun 26, 2020.
HTX-011, an investigational agent, is a dual-acting, fixed-dose combination of the local anesthetic bupivacaine, with a low dose of the nonsteroidal anti-inflammatory drug meloxicam. The FDA had earlier issued a Complete Response Letter (CRL) regarding the NDA for HTX-011 on Apr 30, 2019 relating to chemistry, manufacturing and controls and non-clinical information.
Heron currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .
NGM Biopharmaceuticals Reports Positive Data: NGM Biopharmaceuticals (NASDAQ:NGM) announced positive preliminary topline results from a mid-stage study on aldafermin. The 24-week double-blind, randomized, placebo-controlled cohort (Cohort 4) of an adaptive phase II study evaluating the efficacy, safety and tolerability of 1 mg aldafermin in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH) with stage 2 or 3 liver fibrosis (F2-F3).
Get The News You Want
Aldafermin is an engineered variant of the human hormone FGF19 being developed as a once-daily treatment for patients with NASH. 22% of aldafermin-treated patients versus 0% placebo achieved composite endpoint of both fibrosis improvement and resolution of NASH. The data showed clinically-meaningful response rates of 38% of patients treated with aldafermin having liver fibrosis improvement of ≥1 stage and 24% of patients achieving resolution of NASH at 24 weeks.
Performance
The Nasdaq Biotechnology index lost 0.08% in the last four trading sessions. Among the biotech giants, Incyte gained 4.15% during this period. Over the past six months, shares of Biogen (NASDAQ:BIIB) have gained 43.01%. (See the last biotech stock roundup here: Biotech Stock Roundup: INCY's Solid Q4 Results, EPZM & SGEN's Pipeline Updates ).
What's Next in Biotech?
Stay tuned for more pipeline updates.
Zacks Top 10 Stocks for 2020
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2020?
Last year's 2019 Zacks Top 10 Stocks portfolio returned gains as high as +102.7%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys.
Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.